Form 4 for EDVA Endovia Health Sciences, Inc.
Accepted 2025-10-15 00:00:00 ET · period of report 2024-03-05 · accession 0001731122-25-001385 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-10-15 | 2024-03-05 | EDVA | Nistico Robert | CEO, COB, Dir | A - Grant | $0.00 | +4,000 | 38.1K | +12% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-05 | A | A | 4,000 | $0.00 | 38,053 | D | — | — | (F1) The grant of the Issuer's restricted common stock was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Board of Directors. The shares of restricted common stock are fully vested. (F2) Gives effect to a reverse stock split of 1-for-40 effective March 27, 2025. (F3) The amount beneficially owned will not reconcile to prior Form 4s due to a scriveners error. |